Results announcement for the third quarter 2013

GSK announces Q3 core EPS growth of 16% and dividend of 19p

• Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
• Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%,
• Consumer Healthcare +4%
• Four approvals in three markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
• Q3 dividend of 19p (+6%)
• Full year 2013 guidance reaffirmed

View full Q3 2013 results (PDF)

More information including including CFO interview are available in the quarterly results section of this website.